JP6787995B2 - 細胞毒性ベンゾジアゼピン誘導体の調製方法 - Google Patents
細胞毒性ベンゾジアゼピン誘導体の調製方法 Download PDFInfo
- Publication number
- JP6787995B2 JP6787995B2 JP2018502791A JP2018502791A JP6787995B2 JP 6787995 B2 JP6787995 B2 JP 6787995B2 JP 2018502791 A JP2018502791 A JP 2018502791A JP 2018502791 A JP2018502791 A JP 2018502791A JP 6787995 B2 JP6787995 B2 JP 6787995B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- salt
- reagent
- reacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C[C@@](C(N[C@@](C)C(Nc1cc(CO)cc(COP)c1)=O)=O)NC(CCCCC(*)=O)=O Chemical compound C[C@@](C(N[C@@](C)C(Nc1cc(CO)cc(COP)c1)=O)=O)NC(CCCCC(*)=O)=O 0.000 description 47
- ROVBYDCETXMZLN-NSHDSACASA-N COc(c(O)c1)cc2c1N=C[C@H](Cc1ccccc11)N1C2=O Chemical compound COc(c(O)c1)cc2c1N=C[C@H](Cc1ccccc11)N1C2=O ROVBYDCETXMZLN-NSHDSACASA-N 0.000 description 7
- CDNFJWMYFUTPRD-KYJUHHDHSA-N COc(cc(c(NC[C@H](C1)N2c3c1cccc3)c1)C2=O)c1OCc1cc([N+]([O-])=O)cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)c1 Chemical compound COc(cc(c(NC[C@H](C1)N2c3c1cccc3)c1)C2=O)c1OCc1cc([N+]([O-])=O)cc(COc(c(OC)c2)cc(N=C[C@H]3N4c5ccccc5C3)c2C4=O)c1 CDNFJWMYFUTPRD-KYJUHHDHSA-N 0.000 description 2
- GNTXGZAHEBHSKY-UHFFFAOYSA-N CCOCc1cc([N+]([O-])=O)cc(COc(cc(c(C(N(CC2)C3=C2C=CCC3)=O)c2)N=C)c2OC)c1 Chemical compound CCOCc1cc([N+]([O-])=O)cc(COc(cc(c(C(N(CC2)C3=C2C=CCC3)=O)c2)N=C)c2OC)c1 GNTXGZAHEBHSKY-UHFFFAOYSA-N 0.000 description 1
- XOCJBGONEJWIDQ-IBGZPJMESA-N COc(c(OCc1cc(COI)cc([N+]([O-])=O)c1)c1)cc2c1NC[C@H](Cc1c3cccc1)N3C2=O Chemical compound COc(c(OCc1cc(COI)cc([N+]([O-])=O)c1)c1)cc2c1NC[C@H](Cc1c3cccc1)N3C2=O XOCJBGONEJWIDQ-IBGZPJMESA-N 0.000 description 1
- DEXQJGYKHCNXLU-UHFFFAOYSA-N COc(cc(C(N(CC1)C2=C1C=CCC2)=O)c(N=C)c1)c1OCc1cc([N+]([O-])=O)cc(CI)c1 Chemical compound COc(cc(C(N(CC1)C2=C1C=CCC2)=O)c(N=C)c1)c1OCc1cc([N+]([O-])=O)cc(CI)c1 DEXQJGYKHCNXLU-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/26—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids
- C07C303/28—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of esters of sulfonic acids by reaction of hydroxy compounds with sulfonic acids or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195023P | 2015-07-21 | 2015-07-21 | |
| US62/195,023 | 2015-07-21 | ||
| US201662327973P | 2016-04-26 | 2016-04-26 | |
| US62/327,973 | 2016-04-26 | ||
| PCT/US2016/043406 WO2017015496A1 (en) | 2015-07-21 | 2016-07-21 | Methods of preparing cytotoxic benzodiazepine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020180147A Division JP6995178B2 (ja) | 2015-07-21 | 2020-10-28 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526340A JP2018526340A (ja) | 2018-09-13 |
| JP2018526340A5 JP2018526340A5 (enExample) | 2019-08-29 |
| JP6787995B2 true JP6787995B2 (ja) | 2020-11-18 |
Family
ID=56557925
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502791A Expired - Fee Related JP6787995B2 (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2018502800A Withdrawn JP2018522018A (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2018502785A Active JP6858745B2 (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2020180147A Expired - Fee Related JP6995178B2 (ja) | 2015-07-21 | 2020-10-28 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2021049502A Active JP7337114B2 (ja) | 2015-07-21 | 2021-03-24 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2021202215A Active JP7334228B2 (ja) | 2015-07-21 | 2021-12-14 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2023132536A Withdrawn JP2023162264A (ja) | 2015-07-21 | 2023-08-16 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2023134420A Withdrawn JP2023166434A (ja) | 2015-07-21 | 2023-08-22 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502800A Withdrawn JP2018522018A (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2018502785A Active JP6858745B2 (ja) | 2015-07-21 | 2016-07-21 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2020180147A Expired - Fee Related JP6995178B2 (ja) | 2015-07-21 | 2020-10-28 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2021049502A Active JP7337114B2 (ja) | 2015-07-21 | 2021-03-24 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2021202215A Active JP7334228B2 (ja) | 2015-07-21 | 2021-12-14 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2023132536A Withdrawn JP2023162264A (ja) | 2015-07-21 | 2023-08-16 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
| JP2023134420A Withdrawn JP2023166434A (ja) | 2015-07-21 | 2023-08-22 | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (11) | US9890179B2 (enExample) |
| EP (7) | EP3325483B1 (enExample) |
| JP (8) | JP6787995B2 (enExample) |
| KR (5) | KR20180038460A (enExample) |
| CN (5) | CN113087763A (enExample) |
| AU (7) | AU2016297608B2 (enExample) |
| CA (4) | CA3227588A1 (enExample) |
| CY (2) | CY1122553T1 (enExample) |
| DK (2) | DK3325483T3 (enExample) |
| ES (4) | ES2933376T3 (enExample) |
| HK (1) | HK1252322A1 (enExample) |
| HR (1) | HRP20201479T1 (enExample) |
| HU (1) | HUE051541T2 (enExample) |
| IL (10) | IL286788B2 (enExample) |
| LT (2) | LT3325482T (enExample) |
| PL (2) | PL3325483T3 (enExample) |
| PT (2) | PT3325482T (enExample) |
| RS (2) | RS60840B1 (enExample) |
| RU (3) | RU2727151C2 (enExample) |
| SG (2) | SG10202009354SA (enExample) |
| SI (2) | SI3325482T1 (enExample) |
| SM (2) | SMT202000004T1 (enExample) |
| WO (3) | WO2017015495A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018524387A (ja) * | 2015-07-21 | 2018-08-30 | イミュノジェン・インコーポレーテッド | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3433875B1 (de) | 2016-03-22 | 2022-05-04 | EV Group E. Thallner GmbH | Verfahren zum bonden von substraten |
| CN118359704A (zh) | 2016-10-19 | 2024-07-19 | 英温拉公司 | 抗体构建体 |
| EA201991204A1 (ru) | 2016-12-22 | 2019-12-30 | Университа Дельи Студи Манья Греча Катандзаро | Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43 |
| AU2018213202B2 (en) | 2017-01-25 | 2022-03-24 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
| WO2019234136A1 (en) | 2018-06-05 | 2019-12-12 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
| SG11202104423XA (en) * | 2018-11-12 | 2021-05-28 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| CN112996792B (zh) * | 2018-11-12 | 2024-04-26 | 伊缪诺金公司 | 制备细胞毒性苯并二氮杂卓衍生物的方法 |
| CN113661172A (zh) * | 2019-03-29 | 2021-11-16 | 伊缪诺金公司 | 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物 |
| AU2023298568A1 (en) | 2022-06-30 | 2025-01-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3860600A (en) | 1972-07-10 | 1975-01-14 | Sterling Drug Inc | Octahydropyrrido{8 2,1-c{9 {8 1,4{9 benzodiazepines |
| US3763183A (en) | 1972-07-10 | 1973-10-02 | Sterling Drug Inc | 1,2,3,10,11,11a-hexahydro-5h-pyrrolo (2,1-c)(1,4)benzodiazepines |
| US4678784A (en) | 1984-04-11 | 1987-07-07 | Mcneilab, Inc. | Method for the treatment of LHRH diseases and conditions |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| GB9205051D0 (en) | 1992-03-09 | 1992-04-22 | Cancer Res Campaign Tech | Pyrrolobenzodiazepine derivatives,their preparation,and compositions containing them |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| DK1193270T3 (da) | 1998-08-27 | 2003-09-15 | Spirogen Ltd | Pyrrolobenzodiazepiner |
| GB9818731D0 (en) | 1998-08-27 | 1998-10-21 | Univ Portsmouth | Compounds |
| CA2388063C (en) | 1999-11-24 | 2010-06-08 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
| US6548042B2 (en) * | 2000-08-07 | 2003-04-15 | Arstad Erik | Bis-phosphonate compounds |
| UA75093C2 (en) * | 2000-10-06 | 2006-03-15 | Dimensional Pharm Inc | Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| MXPA05001390A (es) | 2002-08-02 | 2005-07-29 | Immunogen Inc | Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico. |
| JP2006500364A (ja) | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用 |
| RU2314309C2 (ru) | 2003-03-31 | 2008-01-10 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | Пирроло [2.1-c][1.4] бензодиазепины, способ их получения и фармацевтическая композиция на их основе |
| RU2338747C2 (ru) | 2003-03-31 | 2008-11-20 | Каунсил Оф Сайентифик Энд Индастриал Рисерч | ДИМЕРЫ ПИРРОЛО [2, 1-c][1, 4] БЕНЗОДИАЗЕПИНА В КАЧЕСТВЕ ПРОТИВООПУХОЛЕВЫХ СРЕДСТВ И СПОСОБ ИХ ПОЛУЧЕНИЯ |
| AU2003215810B2 (en) | 2003-03-31 | 2009-06-18 | Council Of Scientific And Industrial Research | Pyrrolo((2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof |
| AU2003215821B2 (en) | 2003-03-31 | 2009-04-23 | Council Of Scientific And Industrial Research | Non-cross-linking pyrrolo(2,1-c)(1,4)benzodiazepines as potential antitumour agents and process thereof |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| ATE516288T1 (de) | 2003-10-22 | 2011-07-15 | Us Gov Health & Human Serv | Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren |
| WO2005063759A1 (en) | 2003-12-31 | 2005-07-14 | Council Of Scientific And Industrial Research | PROCESS FOR PREPARING PYRROLO[2, 1-c] [1, 4] BENZODIAZEPINE HYBRIDS |
| GB0404578D0 (en) | 2004-03-01 | 2004-04-07 | Spirogen Ltd | Pyrrolobenzodiazepines |
| CA2558195C (en) * | 2004-03-01 | 2012-11-06 | Spirogen Limited | 11-hydroxy-5h-pyrrolo[2,1-c][1,4]benzodiazepin-5-one derivatives as key intermediates for the preparation of c2 substituted pyrrolobenzodiazepines |
| GB0410725D0 (en) | 2004-05-13 | 2004-06-16 | Spirogen Ltd | Pyrrolobenzodiazepine therapeutic agents |
| GB0412492D0 (en) * | 2004-06-04 | 2004-07-07 | Sterix Ltd | Compound |
| GB0508084D0 (en) * | 2005-04-21 | 2005-06-01 | Spirogen Ltd | Pyrrolobenzodiazepines |
| AU2006238686B2 (en) | 2005-04-21 | 2011-10-06 | Medimmune Limited | Pyrrolobenzodiazepines |
| ATE427949T1 (de) | 2005-10-05 | 2009-04-15 | Spirogen Ltd | 4-a4-(5-oxo-2,3,5,11a-tetrahydro-5h-pyrrolo a2, 1-cua1,4ubenzodiazepin-8-yloxy)-butyrylaminou-1 - pyrrol-2-carbonsaurealkylesterderivate und verwandte verbindung zur behandlung einer proliferativen erkrankung |
| EP1979349B1 (en) * | 2005-12-21 | 2010-07-28 | Abbott Laboratories | Anti-viral compounds |
| DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
| WO2007093873A1 (en) | 2006-02-13 | 2007-08-23 | Council Of Scientific And Industrial Research | Bis-pyrr0l0[2,l-c] [1, 4] benzodiazepine- anthraquinone conjugates as antitumour agents and a process for the preparation thereof |
| HRP20140172T1 (hr) | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| DK2019104T3 (da) | 2007-07-19 | 2013-12-16 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater, og terapeutisk anvendelse deraf |
| ATE543826T1 (de) | 2007-08-01 | 2012-02-15 | Council Scient Ind Res | Als selektive antitumormittel geeignete pyrroloä2,1-cüä1,4übenzodiazepinglycosid-prodru s |
| CN102076717B (zh) | 2008-04-30 | 2016-02-03 | 伊缪诺金公司 | 交联剂和它们的用途 |
| BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
| GB0822260D0 (en) * | 2008-12-05 | 2009-01-14 | Merten Christoph | Assay |
| EP2383263B1 (en) * | 2008-12-30 | 2014-04-16 | Industry-academic Cooperation Foundation, Chosun University | Novel thiazolidinedione derivative and use thereof |
| US8426402B2 (en) | 2009-02-05 | 2013-04-23 | Immunogen, Inc. | Benzodiazepine derivatives |
| JP2013506709A (ja) | 2009-10-06 | 2013-02-28 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| WO2011071078A1 (ja) * | 2009-12-08 | 2011-06-16 | 国立大学法人岐阜大学 | 芳香族化合物、並びに、それを用いたオリゴヌクレオチド誘導体合成用修飾担体、オリゴヌクレオチド誘導体及びオリゴヌクレオチド構築物 |
| US8962279B2 (en) * | 2009-12-30 | 2015-02-24 | Intel Corporation | Solid-phase chelators and electronic biosensors |
| SG10201501062SA (en) * | 2010-02-11 | 2015-04-29 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| SG10201501342UA (en) | 2010-02-24 | 2015-04-29 | Immunogen Inc | Folate receptor 1 antibodies and immunoconjugates and uses thereof |
| US20110256157A1 (en) | 2010-04-15 | 2011-10-20 | Spirogen Limited | Pyrrolobenzodiazepines and conjugates thereof |
| NZ602932A (en) * | 2010-04-15 | 2014-08-29 | Seattle Genetics Inc | Targeted pyrrolobenzodiazapine conjugates |
| CN102971329B (zh) | 2010-04-15 | 2016-06-29 | 麦迪穆有限责任公司 | 用于治疗增殖性疾病的吡咯并苯并二氮杂卓 |
| IL279304B (en) | 2011-02-15 | 2022-07-01 | Immunogen Inc | Method for producing an indolinobenzodiazepine |
| CN102234253B (zh) * | 2011-06-02 | 2013-07-03 | 重庆莱美药业股份有限公司 | 一种制备非布索坦中间体的方法 |
| EP2887965A1 (en) | 2012-08-22 | 2015-07-01 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| CN105683163B (zh) * | 2013-10-04 | 2018-11-09 | 诺华股份有限公司 | RNA干扰中使用的RNAi剂的3’端帽 |
| CN104628772A (zh) | 2013-11-07 | 2015-05-20 | 四川恒康发展有限责任公司 | 一种抗肿瘤前药及其激活剂、组合物和应用 |
| CN103664896B (zh) * | 2013-11-25 | 2016-03-02 | 济南精合医药科技有限公司 | 一种抗肿瘤分子靶向药物克里唑替尼的合成工艺方法 |
| PT3189056T (pt) * | 2014-09-03 | 2020-09-04 | Immunogen Inc | Derivados citotóxicos de benzodiazepina |
| EP3189057A1 (en) | 2014-09-03 | 2017-07-12 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
| JP2017529837A (ja) * | 2014-09-03 | 2017-10-12 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤を含む複合体 |
| KR20180038460A (ko) | 2015-07-21 | 2018-04-16 | 이뮤노젠 아이엔씨 | 세포독성 벤조다이아제핀 유도체의 제조 방법 |
| DK3380525T3 (da) * | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
-
2016
- 2016-07-21 KR KR1020187005040A patent/KR20180038460A/ko not_active Withdrawn
- 2016-07-21 SI SI201630923T patent/SI3325482T1/sl unknown
- 2016-07-21 ES ES19200626T patent/ES2933376T3/es active Active
- 2016-07-21 IL IL286788A patent/IL286788B2/en unknown
- 2016-07-21 PL PL16745961T patent/PL3325483T3/pl unknown
- 2016-07-21 HU HUE16745598A patent/HUE051541T2/hu unknown
- 2016-07-21 PL PL16745598T patent/PL3325482T3/pl unknown
- 2016-07-21 SM SM20200004T patent/SMT202000004T1/it unknown
- 2016-07-21 US US15/216,517 patent/US9890179B2/en not_active Expired - Fee Related
- 2016-07-21 JP JP2018502791A patent/JP6787995B2/ja not_active Expired - Fee Related
- 2016-07-21 LT LTEP16745598.9T patent/LT3325482T/lt unknown
- 2016-07-21 WO PCT/US2016/043402 patent/WO2017015495A1/en not_active Ceased
- 2016-07-21 CN CN202110366892.7A patent/CN113087763A/zh active Pending
- 2016-07-21 AU AU2016297608A patent/AU2016297608B2/en not_active Ceased
- 2016-07-21 RS RS20201132A patent/RS60840B1/sr unknown
- 2016-07-21 KR KR1020247012816A patent/KR20240055894A/ko not_active Withdrawn
- 2016-07-21 EP EP16745961.9A patent/EP3325483B1/en active Active
- 2016-07-21 RU RU2018105756A patent/RU2727151C2/ru active
- 2016-07-21 CN CN201680053120.5A patent/CN108055844A/zh active Pending
- 2016-07-21 DK DK16745961.9T patent/DK3325483T3/da active
- 2016-07-21 IL IL305989A patent/IL305989A/en unknown
- 2016-07-21 EP EP22195446.4A patent/EP4163284A1/en not_active Withdrawn
- 2016-07-21 KR KR1020187005041A patent/KR102660070B1/ko active Active
- 2016-07-21 WO PCT/US2016/043406 patent/WO2017015496A1/en not_active Ceased
- 2016-07-21 CN CN201680053093.1A patent/CN108026103B/zh not_active Expired - Fee Related
- 2016-07-21 LT LTEP16745961.9T patent/LT3325483T/lt unknown
- 2016-07-21 KR KR1020187003181A patent/KR102659706B1/ko active Active
- 2016-07-21 SM SM20200506T patent/SMT202000506T1/it unknown
- 2016-07-21 HK HK18111602.7A patent/HK1252322A1/zh unknown
- 2016-07-21 US US15/216,548 patent/US10081640B2/en active Active
- 2016-07-21 HR HRP20201479TT patent/HRP20201479T1/hr unknown
- 2016-07-21 CA CA3227588A patent/CA3227588A1/en active Pending
- 2016-07-21 CN CN202110219412.4A patent/CN113004288A/zh active Pending
- 2016-07-21 PT PT167455989T patent/PT3325482T/pt unknown
- 2016-07-21 ES ES20181645T patent/ES2959741T3/es active Active
- 2016-07-21 EP EP19200626.0A patent/EP3653628B1/en active Active
- 2016-07-21 CN CN201680051138.1A patent/CN108290895B/zh not_active Expired - Fee Related
- 2016-07-21 AU AU2016297087A patent/AU2016297087B2/en not_active Ceased
- 2016-07-21 RU RU2018105752A patent/RU2018105752A/ru not_active Application Discontinuation
- 2016-07-21 PT PT167459619T patent/PT3325483T/pt unknown
- 2016-07-21 IL IL294651A patent/IL294651B2/en unknown
- 2016-07-21 IL IL305279A patent/IL305279A/en unknown
- 2016-07-21 JP JP2018502800A patent/JP2018522018A/ja not_active Withdrawn
- 2016-07-21 AU AU2016297607A patent/AU2016297607A1/en not_active Abandoned
- 2016-07-21 EP EP23183947.3A patent/EP4286387A3/en not_active Withdrawn
- 2016-07-21 SG SG10202009354SA patent/SG10202009354SA/en unknown
- 2016-07-21 SG SG10202106529XA patent/SG10202106529XA/en unknown
- 2016-07-21 US US15/216,512 patent/US9873708B2/en active Active
- 2016-07-21 EP EP16745598.9A patent/EP3325482B1/en active Active
- 2016-07-21 JP JP2018502785A patent/JP6858745B2/ja active Active
- 2016-07-21 ES ES16745598T patent/ES2820358T3/es active Active
- 2016-07-21 DK DK16745598.9T patent/DK3325482T3/da active
- 2016-07-21 EP EP16748205.8A patent/EP3325485B1/en active Active
- 2016-07-21 EP EP20181645.1A patent/EP3778602B1/en active Active
- 2016-07-21 WO PCT/US2016/043414 patent/WO2017015502A1/en not_active Ceased
- 2016-07-21 RU RU2018105609A patent/RU2746322C2/ru active
- 2016-07-21 CA CA2991305A patent/CA2991305C/en active Active
- 2016-07-21 ES ES16745961T patent/ES2764548T3/es active Active
- 2016-07-21 IL IL283355A patent/IL283355B/en unknown
- 2016-07-21 SI SI201630578T patent/SI3325483T1/sl unknown
- 2016-07-21 KR KR1020247012991A patent/KR20240055903A/ko not_active Withdrawn
- 2016-07-21 CA CA2991326A patent/CA2991326A1/en not_active Abandoned
- 2016-07-21 CA CA2992082A patent/CA2992082A1/en active Pending
- 2016-07-21 RS RS20191647A patent/RS59806B1/sr unknown
-
2017
- 2017-12-11 US US15/837,832 patent/US10370389B2/en active Active
-
2018
- 2018-01-03 US US15/860,864 patent/US10392407B2/en not_active Expired - Fee Related
- 2018-01-11 IL IL256854A patent/IL256854A/en unknown
- 2018-01-11 IL IL256860A patent/IL256860B/en active IP Right Grant
- 2018-01-11 IL IL256861A patent/IL256861B/en active IP Right Grant
- 2018-09-12 US US16/129,008 patent/US10899775B2/en active Active
-
2019
- 2019-06-06 US US16/433,117 patent/US10787463B2/en active Active
- 2019-06-21 US US16/448,261 patent/US20200017526A1/en not_active Abandoned
- 2019-12-30 CY CY20191101364T patent/CY1122553T1/el unknown
-
2020
- 2020-08-10 IL IL276630A patent/IL276630B/en active IP Right Grant
- 2020-08-10 IL IL276631A patent/IL276631B/en unknown
- 2020-08-12 US US16/991,700 patent/US11420982B2/en active Active
- 2020-09-23 CY CY20201100899T patent/CY1123390T1/el unknown
- 2020-10-28 JP JP2020180147A patent/JP6995178B2/ja not_active Expired - Fee Related
- 2020-11-23 US US17/101,942 patent/US20210171547A1/en not_active Abandoned
-
2021
- 2021-03-24 JP JP2021049502A patent/JP7337114B2/ja active Active
- 2021-04-20 AU AU2021202403A patent/AU2021202403B2/en not_active Ceased
- 2021-05-17 AU AU2021203148A patent/AU2021203148B2/en not_active Ceased
- 2021-12-14 JP JP2021202215A patent/JP7334228B2/ja active Active
-
2022
- 2022-12-14 US US18/080,973 patent/US20230257400A1/en not_active Abandoned
-
2023
- 2023-03-03 AU AU2023201339A patent/AU2023201339A1/en not_active Abandoned
- 2023-04-11 AU AU2023202221A patent/AU2023202221A1/en not_active Abandoned
- 2023-08-16 JP JP2023132536A patent/JP2023162264A/ja not_active Withdrawn
- 2023-08-22 JP JP2023134420A patent/JP2023166434A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018524387A (ja) * | 2015-07-21 | 2018-08-30 | イミュノジェン・インコーポレーテッド | 細胞毒性ベンゾジアゼピン誘導体の調製方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6995178B2 (ja) | 細胞毒性ベンゾジアゼピン誘導体の調製方法 | |
| HK40088821A (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| HK40029973A (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| HK40029973B (en) | Methods of preparing cytotoxic benzodiazepine derivatives | |
| HK1252323B (en) | Methods of preparing cytotoxic benzodiazepine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180322 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190719 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190719 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200611 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200615 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200915 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201002 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201029 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6787995 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |